CAPS to Showcase Latest 503B Quality Assurance Capabilities and Expansion Plansat Health Connect Reverse Expo – Fall Hospital Pharmacy Conference
IRVINE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS®), will showcase its sustained commitment to improving patient safety at the 2017 Health Connect Conference in Chicago, IL, Oct. 16-18.
At booth #508, CAPS representatives will introduce the company’s latest 90-Day Beyond Use Dating (BUD) quality assurance offering for pre-filled syringes and other products, which is designed to improve the waste reduction process. This initiative further complements CAPS’ current extended BUD offerings.
CAPS has been a front-runner in implementing the Food and Drug Administration’s (FDA) 503B quality assurance requirements under the Drug Quality and Security Act. During the conference, CAPS will highlight its Test, Hold and ReleaseSM (THR®) program, which is designed to ensure that every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new standards for 100% cGMP release testing for sterility, potency, and endotoxin prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.
“Our existing high quality standards are strengthened with THR implementation,” said Mike Koch, Senior Vice President, CAPS Professional Services. “When it comes to patient safety, we believe that 100% release testing from our 503B facilities is the only way to assure the level of quality demanded by our customers.”
CAPS was among the first outsourcing admixture pharmacies in the nation to fully adopt release testing.
“CAPS is at the forefront of helping hospitals and surgery centers navigate through the new compounding regulatory environment,” said Koch. “Our goal is to provide our customers with programs such as THR, and extended BUD to help them focus on improving patient care.”
To further underscore its commitment to servicing its customers and expanding its sterile compounding outsourcing services in the U.S., CAPS will open a new 250,000 square-foot, state-of-the-art facility in Phoenix, AZ, which is expected to open in the summer of 2018. The new facility will be registered with the FDA as a 503B outsourcing facility, to distribute compounded sterile preparations. CAPS has two existing 503B facilities located in San Diego, CA and Allentown, PA.
“With the opening of our third 503B facility, CAPS will enhance productivity and increase capacity, while serving as an economic boost to the local and state economy,” said Tom Wilverding, President of CAPS. “When fully operational the CAPS facility will create nearly 400 new jobs including opportunities for pharmacists, pharmacy technicians, chemists, microbiologists, and other support personnel.”
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.
CAPS is the nation's largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS currently has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including PN and chemotherapy. To learn more, visit www.CAPSpharmacy.com.
Central Admixture Pharmacy Services, Inc. 303.744.7713